RELIEF implements new CHF 50m Share Subscription Facility

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, has signed a binding agreement with its main shareholder GEM Global Yield LLC SCS ("GEM") for the implementation of a new Share Subscription Facility ("SSF") in the amount of up to CHF 50m. GEM is Relief's longest standing shareholder, dating back to their initial investment in 2015, and currently owns over 1.3 bn shares of Relief common stock.

VISCHER advises Relief regarding the Swiss legal aspects of this transaction. The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprises Dr. Peter Kühn (Counsel, Corporate/M&A).

Press release

Robert Bernet

Attorney at Law

• Partner

• +41 58 211 33 51
• [email protected]

Peter Kühn

Attorney at Law

• Counsel

• +41 58 211 36 07
• [email protected]